## Mechanisms of Action

---

Antibody Dependent Cellular Cytotoxicity (ADCC)
<img class="mechimg" src="https://upload.wikimedia.org/wikipedia/commons/thumb/0/05/Antibody-dependent_Cellular_Cytotoxicity.svg/2560px-Antibody-dependent_Cellular_Cytotoxicity.svg.png" alt="ADCC">

<div class="reflink">
<a href="https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity#/media/File:Antibody-dependent_Cellular_Cytotoxicity.svg">Antibody-dependent cellular cytotoxicity</a> by <a href="https://commons.wikimedia.org/w/index.php?title=User:Satchmo2000&action=edit&redlink=1">Satchmo2000</a> licenced under <a href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a>
</div>
---

Complement Mediated Cytotoxicity 
<img class="mechimg" src="https://upload.wikimedia.org/wikipedia/commons/7/79/Rituximab_mechanisms_of_action.jpg" alt="CDC">

<div class="reflink">

[Rituximab mechanisms of action](https://upload.wikimedia.org/wikipedia/commons/7/79/Rituximab_mechanisms_of_action.jpg) by [Seyfizadeh, N., et al., A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Critical Reviews in Oncology / Hematology. 97: p. 275-290.
](https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology) under [CC BY 2.5](https://creativecommons.org/licenses/by/2.5/deed.en)

</div>

---


Lorlatinib
LORBRENDA
02485966
ALK Inhibitor
Anaplastic Lymphocytic Lymphoma Kinase (ALK)
ALK+ NSCLC
3rd Gen inhibitor ALK &#x2F; ROS1.
Overcomes ALK mutations (such as post crizotinib).
T1&#x2F;2: 24hr
CYP3A4
Dose adjust for renal&#x2F;hepatic dysfx
Y
43577
43577
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061480.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97619
---

Brigatinib
ALUNBRIG
02479206
ALK Inhibitor
Anaplastic Lymphocytic Lymphoma Kinase (ALK)
ALK+ NSCLC
Inhibitor ALK, ROS1, IGF-1R, FLT-3, EGFR mutations
Activity against EML4 ALK and 17 mutant ALK (such as progression on crizotinib)
T1&#x2F;2: 25 hr
CYP 2C8 and 3A4
Dose adjust in renal&#x2F;hepatic dysfx
Y
43343
43343
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060201.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96982
---

Alectinib
ALECENSARO
02458136
ALK Inhibitor
Anaplastic Lymphocytic Lymphoma Kinase (ALK)
ALK+ NSCLC
Inhibitor ALK, RET
Note more potent than crizotinib &amp; active against ALK mutations developed on crizotinib
T1&#x2F;2: 33 hr
Major active metabolite M4 T1&#x2F;2: 31hr
3A4
Dose adjust Renal&#x2F;Hepatic dysfnx
Y
42657
42657
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062016.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94518
---

Ceritinib
ZYKADIA
02436779
ALK Inhibitor
Anaplastic Lymphocytic Lymphoma Kinase (ALK)
ALK+ NSCLC
Inhibitor ALK, IGF-1, Insulin receptor, ROS1
activity in crizotinib resistant tumors
T1&#x2F;2: 41hr
3A4
Dose adjust hepatic dysfnx.
Unstudied for renal
Y
42123
42123
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054572.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92108
---

Crizotinib
XALKORI
02384256
ALK Inhibitor
Anaplastic Lymphocytic Lymphoma Kinase (ALK)
ALK+ or ROS1 positive NSCLC
Inhibitor ALK, ROS1, Hepatocyte Growth Factor Receptor
Inducing apoptosis in cell lines with mutations
T1&#x2F;2: 42hr
3A4&#x2F;5
Dose adjust Renal&#x2F;Hepatic dysfnx
Y
41039
41039
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059902.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86999
---

Blinatumomab
BLINCYTO
02450283
Anti-CD19&#x2F;3 BiTE
CD19 B Cell &#x2F; Cd3 T Cell
Acute Lymphocytic Leukemia PH-ve with MDR
ALL relapse
Both Pediatric and adult
Bispecific T-Cell Engager (BITE) binds to CD 19 of B cells and CD3 of T cells creating a connection between the two.
Mediates cytolytic proteins, inflammatory cytokins and lysis of CD 19 B cells
T1&#x2F;2: Approx 2 hr
No adjustments
N
42446
42446
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060888.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93642
---

Obintutuzumab
GAZYVA
02434806
Anti-CD20 Monoclonal Antibody
CD20 B Lymphocytes
CLL in combo with chemotherapy
Follicular Lymphoma in combo with chemotherapy
Monoclonal targeting CD 20+ B lymphocytes
ADCC&#x2F;CDC, antibody depentent cellular phagocytosis
Binds more strongly than rituxan.
High risk of reactions especially with high tumor burden
T1&#x2F;2: 25-35 days
No adjustments
N
41971
41971
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059907.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91910
---

Rituximab
RITUXAN
02241927
Anti-CD20 Monoclonal Antibody
CD20 B Lymphocytes
NHL, CLL 
In combination with chemo or alone
Monoclonal targeting CD 20+ B lymphocytes
ADCC&#x2F;CDC, antibody depentent cellular phagocytosis
T1&#x2F;2 days to months
No adjustments
N
36605
36605
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00053554.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;65597
---

Isatuximab
SARCLISA
02498235
Anti-CD38 Monoclonal Antibody
CD38 Tumor Cells
In combination with pom&#x2F;dex for relapse refactory myeloma
Monoclonal targeting CD 38 expressed on hematopoeitic and tumor cells including myeloma.
ADCC&#x2F;CDC
++ risk of reactions
No adjustments
Contains polysorbate 80 (reactions)
N
44015
44015
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060885.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98801
---

Daratumumab
DARZALEX
02455951
Anti-CD38 Monoclonal Antibody
CD38 Hematologic Malignancy (Myeloma)
In combination with borez&#x2F;thalidomide&#x2F;dex,
len&#x2F;dex, bortez&#x2F;melphalan&#x2F;pred for relapse refractory myeloma
Monoclonal targeting CD 38 expressed on hematopoeitic and tumor cells including myeloma.
ADCC&#x2F;CDC
++ risk of reactions
T1&#x2F;2: 18 days +&#x2F;- 9 d
N
42563
42563
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062011.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94282
---

Pralatrexate
FOLOTYN
02481820
Antimetabolite
DNA
Peripheral T Cell Lymphoma - Relapse&#x2F;refractory
Antifolate analog - inhibits DNA&#x2F;RNA by inhibiting dihydrofolate reductase
Competes for DHFR-folate binding site
T1&#x2F;2 12-18 hr
Substrate BCRP&#x2F;ABCG2
Dose adjust for significant renal dysfxn or grade 3+ hepatotoxicity

N
43480
43480
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047981.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97230
---

Trifluridine-tipiracil
LONSURF
02472104
Antimetabolite
DNA
met colorectal ca previously treated
met gastric or GE junction ca previously treated
Trifluridine - thymidine-based analogue inhibiting DNA
Tipiracil - thymidine phosphoralase inhibitor preventing breakdown of trifluridine
T1&#x2F;2 Trifluridine 2.1hr, tipiracil 2.4 hr
Many dose reduction criteria
Both hepatic and renal dose adj
Y
43181
43181
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058926.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96138
---

Capecitabine
XELODA
02238453
Antimetabolite
DNA
Colorectal (adj&#x2F;met) and breast (advanced) ca
Prodrug of fluorouracil - activated in the liver and tissues.
Pyrimidine antimetabolite inhibiting thymidylate synthetase
T1&#x2F;2: 0.75 hr
Metabolized to fluorouracil (T1&#x2F;2: 8-20min)
CYP2C9 weak inhibitor
Many interactions which affect drug levels
Y
36048
36048
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060777.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;61873
---

Thioguanine
LANVIS
00282081
Antimetabolite
DNA
Acute Leukaemia (ALL)
Purine analogue of guanine inhibiting DNA - blocks synthesis and metabolism of purines
T1&#x2F;2: 5-9 hr
No labelled renal adjustment.
May adjust for hepatic toxicity
**thiopurine methyltransferase testing may be required as this affects metabolism
Y
27394
42746
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050561.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1812
---

Mercaptopurine
PURINETHOL
00004723
Antimetabolite
DNA
Acute Leukaemia (ALL)
Purine antagonist inhibiting DNA.
T1&#x2F;2: 1.3hr
Metabolized by xanthine oxidase (interaction!)
Active metabolites
TPMT testing**

Y
20089
41717
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00025910.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;960
---

Acalabrutinib
CALQUENCE
02491788
BTK Inhibitor
Bruton&#39;s Tyrosine Kinase
CLL - with obin or monotherapy 1st line
CLL relapse
Mantle Cell Lymphoma
2nd gen Bruton&#39;s Tyrosine Kinase inhibitor
BTK integral to Bcell receptor cytokine pathway for proliferation, trafficking adhesion.
Inhibition decreases malignant cell growth
T1&#x2F;2: 1hr
Active metabolite: 3.5hr
Absorption affected by food
3A4 metabolism
Y
43740
43740
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054129.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98179
---

Ibrutinib
IMBRUVICA
02434407
BTK Inhibitor
Bruton&#39;s Tyrosine Kinase
CLL -with or without 17P deletion 1st line or relapse. May be in combo with chemo
Mantle Cell, maginal zone Lymphoma, wandenstrom&#39;s 
Steroid dependent&#x2F;refractory GVHD

irreversible BTK inhibitor - Decrease malignant B Cell proliferation
T1&#x2F;2: 4-6hr
CYP3A4
Active metabolite
unknown adj for renal
Adjust for Mild hepatic dysfxn
Y
41962
41962
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061285.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91874
---

Inotuzumab Ozogamicin
BESPONSA
02473909
CD22 - MAB-drug conjugate
CD22 Lymphocytes
ALL CD22+ relapse&#x2F;refractory
CD22 MAB drug conjugate with calicheamicin
CD22 is present on B cells in ALL
Ozogamicin causes DNA strand breaks once internalized by the target cell
T1&#x2F;2: 12.3 days
Risk of hepato-occlusive disease
No offical dose adjustments however liver dysfunction must be monitored
N
43223
43223
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044248.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96383
---

Brentuximab vedotin
ADCETRIS
02401347
CD30 - MAB-drug conjugate
CD30 Lymphocytes
Hodgkin Lymphoma, relapse single agent or with chemo
Post auto transplant consolidation
Post transplant relapse
CD 30 MAB drug conjugate with microtubule agent monomethylauristatine E (MMAE)
MMAE is internalized and arrests cell cycle
CD 30 is present on hodgkin&#39;s cells
T1&#x2F;2: 4-6 d
MMAE - chemo 3-4d
MMAE - CYP3A4 Sub
Dose adjust considerations for renal and hepatic dysfx

N
41324
44358
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061748.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88626
---

Gemtuzumab Ozogamicin
MYLOTARG
02494388
CD33 - MAB-drug conjugate
CD33 Myeloid Cells
CD 33+ AML (except APL) in combination with chemotherapy 1st line
CD 33 MAB conjugate with calicheamicin.
After internalization calicheamicin  induces DNA strand breaks and cell arrest
T1&#x2F;2: 62-90 hrs
No dose adjustment for renal&#x2F;hepatic dysfxn
may cause hepatotoxicity requiring held dose
N
43901
43901
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054128.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98440
---

Polatuzumab vedotin
POLIVY
02499614
CD79b - MAB-drug conjugate
CD79b Lymphocytes
DLBCL in combination with bendamustine and rituximab and not eligible to transplant and have at least 1 prior therapy
CD 79b present on B cell surface (such as DLBCL). CD 79b MAB conjugate with MMAE. Once internalized MMAE disrupts tubule network causing cell cycle arrest
T1&#x2F;2: MMAE 4- 12 days
MMAE CYP3A4 Sub
Dose adjust consideration in renal and hepatic dysfxn
N
44160
44160
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060834.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98934
---

Palbociclib
IBRANCE
02493535
CDK 4&#x2F;6 Inhibitor
Cyclin-dependent Kinase
Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant
Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth
T1&#x2F;2: 29h +- 5 hr
3A4 sub
dose reduced in severe hepatic dysfxn
Multiple dose adjustments for toxicities (hematologic&#x2F;pulmonary)
Y
44095
44095
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054832.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98354
---

Abemaciclib
VERZENIO
02487098
CDK 4&#x2F;6 Inhibitor
Cyclin-dependent Kinase
Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant
Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth
T1&#x2F;2: 18hr
3A4 sub
dose adjust in severe hepatic dysfxn
mulitple dose adjustment for toxicities (heme&#x2F;lung&#x2F;nonheme)
Y
43649
43649
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061550.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97723
---

Ribociclib
KISQALI
02473569
CDK 4&#x2F;6 Inhibitor
Cyclin-dependent Kinase
Breast ca, hormone receptor positive, HER2 -ve advanced disease in combination with aromatase or fulvestrant
Cycline dependent kinase CDK 4 and 6, regulate cell cycle (G1&#x2F;2s phase). Inhibits CDK4&#x2F;6 causing downsteam signaling to inhibit breast ca cell line growth
T1&#x2F;2: 30-55 hr
3A4 sub
both renal and hepatic dose adj
Multiple dose adjustment for toxicities (heme&#x2F;lung&#x2F;skin&#x2F;other non heme)

Y
43217
43217
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059361.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96295
---

Ipilimumab
YERVOY
02379384
CTLA-4 Inhibitor
Cytotoxic T Lymphocyte Associated Antigen
Met melanoma, met renal ca
IgG MAB that binds cytotoxic T-Lymphocyte associated antigen 4 (CTLA-4).
CTLA-4 down regulates T cells and by blocking it T cells are able to be activated against tumor cells (renal ca &#x2F;melanoma)
Used in combination with nivolumab to synergy
T1&#x2F;2: 15.4 days
Unique immune mediated toxicity profile. Dose delays for various toxicities (hepatic, renal, GI, cutaneous, thyroid etc)

N
40976
40976
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060643.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86525
---

Cetuximab
ERBITUX
02271249
EGFR Inhibitor
Epidermal Growth Factor Receptor
met Colorectal ca (RAS wild) with or without chemotherapy.
Squamous cell ca HN with radiation with or without chemo
MAB to epidermal growth factor receptor which blocks activation of receptor kinases inhibiting cell growth. EGFR activates RAS downstream. RAS mutations result in resistance.
T1&#x2F;2: 112 hrs
No dose adj for renal&#x2F;hepatic however for toxicities (dematologic, infusion reactions, pulmonary tox)
** infusion reactions
N
39749
40298
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043071.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75672
---

Panitumumab
VECTIBIX
02308487
EGFR Inhibitor
Epidermal Growth Factor Receptor
met Colorectal ca (RAS wild) with or without chemotherapy.
MAB to epidermal growth factor receptor which blocks activation of receptor kinases inhibiting cell growth. EGFR activates RAS downstream. RAS mutations result in resistance.
T1&#x2F;2: 7.5 days
Dose adjustments for toxicities but not renal&#x2F;hepatic dysfxn
N
39595
39595
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00038772.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;79412
---

Gilteritinib
XOSPATA
02495058
FLT3 Inhibitor
FMS Like Tyrosine Kinase 3
AML FLT3 +, Refractory or Relapsed
Inhibits FMS-like tyrosine kinase mutations (FLT3).
Mutated FLT3 signals cell proliferation in leukemic cells that express it.
T1&#x2F;2: 113 hrs
Onset within 24 hrs
CYP 3A4
Dose adjustments not studied in renal&#x2F;hepatic dysfxn

Y
43864
43864
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054411.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98500
---

Midostaurin
RYDAPT
02466236
FLT3 Inhibitor
FMS Like Tyrosine Kinase 3
AML FLT3 +, induction and consolidation
FLT3 Tyrosine kinase inhibition (also wild type FLT3, KIT, PDGFR, serine&#x2F;threonine protein kinase) leading to apoptosis of leukemic cells
T1&#x2F;2: 19 hr, longer for active metabolites (up to 482 hr)
CYP 3A4
No adjustments for renal&#x2F;hepatic
Y
42937
42937
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061996.PDF">HC Link</a>

---

Dinutuximab
UNITUXIN
02483076
GD2
glycolipid disialoganglioside (GD2)
High risk neuroblastoma in pediatric patients with partial response to initial therapy. In combination with GM-CSF&#x2F;IL2&#x2F;CisRetinoicAcid
MAB targeting GD2, a cell surface protein in neurons (neuroblastoma). Induces apoptosis (ADCC&#x2F;CDC)
T1&#x2F;2: 10 days
no dose adjustment for renal&#x2F;hepatic dysfxn
**Serious infusion reactions.
Requires opioid infusion.
Severe neuropathy&#x2F;neurotoxicity.
N
43586
43586
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00048647.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97347
---

Sonidegib
ODOMZO
02500337
Hedgehog Pathway Inhibitor
Smoothen (SMO) Receptor
Basal cell ca, locally advanced, not amenable to curative radiation&#x2F;surgery
Hedghog pathway regulates cell growth and differentiation in embryogenesis. Inactive in adults but is activated in basel cell ca.
Binds to smoothened homologue (SMO) involved in pathway signaling.
T1&#x2F;2: 28 days
CYP3A4
No labelled dose reduction for renal&#x2F;hepatic dysfxn though adjusted for CK increases
Y
44188
44188
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056602.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;99003
---

Vismodegib
ERIVEDGE
02409267
Hedgehog Pathway Inhibitor
Smoothen (SMO) Receptor
Basal cell ca, locally advanced, not amenable to curative radiation&#x2F;surgery
Hedghog pathway regulates cell growth and differentiation in embryogenesis. Inactive in adults but is activated in basel cell ca.
Binds to smoothened homologue (SMO) involved in pathway signaling.
T1&#x2F;2: 4d
not significantly metabolized by CYP
No dose adjustments listed but may need to be held for toxicities (cutaneous)
Y
41495
41495
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056365.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89398
---

Trastuzumab
HERCEPTIN
02480697
HER2 Inhibitor
Human Epidermal Growth Factor Receptor
Breast ca, HER2 positive, (neo)adjuvant with chemo or metastatic
HER2 protein is overexpressed in some breast cancers. MAB - targeting of HER2 inducing ADCC
No dose adjustments for hepatic or renal dysfxn
May need to be held for LVEF decreases
N
43385
43385
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056300.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97124
---

Pertuzumab
PERJETA
02405016
HER2 Inhibitor
Human Epidermal Growth Factor Receptor
Breast ca, HER2 positive, (neo)adjuvant with chemo or metastatic
Binds to HER2 at seperate site from trastuzumab. Used in combination for more compete inhibition of HER 2 in Breast Ca overexpressing HER2
T1&#x2F;2: 18d
No dose adjustment for renal or hepatic dysfxn
held if (along with tras) for LVEF decreases
N
41402
41402
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060125.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88984
---

Lapatinib
TYKERB
02326442
HER2 Inhibitor
Human Epidermal Growth Factor Receptor
Breast ca, met, HER2+ post chemo, in combo with capecitabine
Approved on surrogate endpint (time to progression)
TKI (EGFR and HER2) blocking cell signaling. May overcome resistance to endocrine therapy in HER2 + hormone receptor pos Breast ca
T1&#x2F;2: 24 hr
CYP 3A4&#x2F;5
Dose adjust in significant hepatic toxicity, cardiac, derm, GI, pulmonary
Y
39969
42479
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00048842.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;81179
---

Darolutamide
NUBEQA
02496348
Hormonal Agent
Androgen Pathway
Prostate cancer, non metastatic castrate resistant
Androgen receptor inhibitor resulting in decreased prostate tumor proliferation, and apoptosis
T1&#x2F;2: 20 hrs
CYP 3A4
dose reduced in renal and hepatic dysfxn as well as toxicities (grade 3 general)
Y
43914
43914
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062165.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98622
---

Siltuximab
SYLVANT
02435128
IL6 inhibitor
IL6
Multicentric Castleman’s Disease
Chimeric antibody to IL2 preventing its binding.
Overproduction of IL6 leads to manifestations of multicentric Castlemans disease. (systemic lymphadenopathy, cytopenias, inflammation, organ dysfunction)
T1&#x2F;2: 21days
Dose adjustments not studies
N
42066
44222
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059834.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91940
---

Niraparib
ZEJULA
02489783
PARP Inhibitor
Poly ADP-ribose polymerase
Advanced ovarian epithelial ca maint post platinum therapy, 1st line or after relapse and are in complete or partial response
inhibits Poly ADP-ribose (PARP-1, PARP-2) which normally detects DNA damage and repair resulting in apoptosis
T1&#x2F;2: 36 hr
Dose adjusted for hepatic dysfxn and various toxicities (cytopenia, GI)
*Risk of MDS&#x2F;AML
Y
43839
43839
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058166.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97986
---

Olaparib
LYNPARZA
02475200
PARP Inhibitor
Poly ADP-ribose polymerase
Breast ca, HER2 -ve, BRCA germline mutation positive, past treament.
Ovarian epithelial BRCA mutated, in response post platinum therapy
Ovarian epithelial platinum sensitive disease in repsonse - maintenance
inhibits Poly ADP-ribose (PARP-1, PARP-2, PARP-3) which normally detects DNA damage and repair resulting in apoptosis
Acts on BRCA 1&#x2F;2 deficient tumors causing DNA breaks that are unable to be repaired
T1&#x2F;2: 14.9 ± 8.2 hours (tabs)
CYP3A4
Dose adjusted in renal dysfxn, and other toxicity (cytopenia, GI, pneumonitis)
*Risk of MDS&#x2F;AML
Y
43243
43243
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061411.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96554
---

Cemiplimab
LIBTAYO
02487152
PD-1&#x2F;PD-L1 Inhibitor
PD-1
Met or locally advanced squamous cell ca ineligibile for surgery or radiation
IgG MAB that binds to PD-1 blocking PD-L1, PD-L2 binding
Results in T cell activation and tumor detection.
T1&#x2F;2: 20 days
No dose adjustments
Immune mediated side effects (Hepatic, GI, cutaneous, pulmonary etc)
N
43609
43609
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058044.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97727
---

Avelumab
BAVENCIO
02469723
PD-1&#x2F;PD-L1 Inhibitor
PD-L1
Met or locally advanced urothelial ca post platinum
Met merkel cell (skin cancer)
MAB restores T cell function by binding to PD-L1 preventing interaction with PD-1 (checkpoint)
T1&#x2F;2: 6.1 d
Immune mediated dose adjustment&#x2F;hold
N
43087
43087
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059619.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95856
---

Durvalumab
IMFINZI
02468816
PD-1&#x2F;PD-L1 Inhibitor
PD-L1
Met or locally advanced urothelial ca post platinum
locally advance NSCLC (stage III) with response post radiation
Extensive stage small cell lung ca with chemo (etop&#x2F;platinum)
MAB - PD-L1 inhibition
T1&#x2F;2: 18d
N
43059
43059
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060587.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95736
---

Pembrolizumab
KEYTRUDA
02456869
PD-1&#x2F;PD-L1 Inhibitor
PD-1
Melanoma, NSCLC, Hodgkin lymphoma, Primary mediastinal B cell, Urothelial, Renal Cell,  Colorectal MSI-H, endometrial, H&amp;N Squamous, Esophageal
MAB - PD-1 inhibition
T1&#x2F;2: 22d
N
42929
42929
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062141.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94388
---

Atezolizumab
TECENTRIQ
02462990
PD-1&#x2F;PD-L1 Inhibitor
PD-L1
Extensive stage small cell lung ca, NSCLC, hepatocellular, locally advanced or met Breast ca, advanced urothelial ca
MAB - PD-L1 inhibition
T1&#x2F;2: 27d
N
42857
42857
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061767.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;95089
---

Nivolumab
OPDIVO
02446626
PD-1&#x2F;PD-L1 Inhibitor
PD-1
advanced or adj melanoma, met NSCLC, advanced mesothelioma, met Renal cell, squamous HN, classic Hodgkin, Hepatocellular, MSI-H met colorectal, adj GEJ
MAB - PD-1 inhibition
T1&#x2F;2: 25 d
N
42300
42300
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062198.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93204
---

Alpelisib
PIQRAY
02497069
PI3 Kinase Inhibitor
Phosphatidylinositol 3 -kinase
Breast ca, with fulvestrant, HR+, HER2-ve, PI3CA mutated advanced disease
Inhibitor of PI3 kinase which decreases cell signaling
T1&#x2F;2: 8-9h
Dose adjusted for various toxicities (derm, GI, glucose,pancreatitis, lung)
Y
44011
44011
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061787.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98692
---

Idelalisib
ZYDELIG
02438798
PI3 Kinase Inhibitor
Phosphatidylinositol 3 -kinase
CLL with ritux in relapse, follicular lymphoma monotherapy in relapse
Inhibits delta form of PI3Kinase present in lymphoid B cells inhibiting chemotaxis, adhesion and viability.
T1&#x2F;2: 8.2hr
3A4 both inhibitor and substrate (strong)
dose adjusted for toxicity (derm, GI, heme, lung,)
Y
42115
42115
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057731.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92318
---

Lacrotrectinib
VITRAKVI
02490315
TRK Inhibitor
Receptor Tyrosine Kinase



Y
44148
44148
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060963.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98037
---

Entrectinib
ROZLYTREK
02495007
TRK Inhibitor
Receptor Tyrosine Kinase



Y
43900
43900
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059544.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;98496
---

Lenvatinib
LENVIMA
02484129
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
43759
43759
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059280.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97445
---

Dacometinib
VIZIMPRO
02486024
Tyrosine Kinase Inhibitor
EGFR&#x2F;HER1 HER2 HER4



Y
43577
43577
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050253.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97625
---

Ramucirumab
Cyramza
02443805
VEGF Inhibitor MAB
VEGF Receptor 2



N
42257
42257
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060742.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92855
---

Bevacizumab
AVASTIN
02270994
VEGF Inhibitor MAB
VEGF



N
38658
38658
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059621.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75642
---

Cyclophosphamide
PROCYTOX
02241795
Alkylating Agent
DNA
multiple
Alkylation and cross-linking DNA strands
T1&#x2F;2: 3-12 hr
2B6 Major
2C9, 3A4, 2A6 2C19 minor
Adjust in significant renal dysfxn
Y
36770
37897
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00017604.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;65460
---

Temozolomide
TEMODAL
02241093
Alkylating Agent
DNA



Y
36476
40983
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00039947.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;64696
---

Hydroxyurea
HYDREA
00465283
Alkylating Agent
DNA



Y
29220
38289
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054980.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;3453
---

Lomustine
CEENU
00360422
Alkylating Agent
DNA



Y
28125
40161
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00033792.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;2530
---

Procarbazine
MATULANE
00012750
Alkylating Agent
DNA



Y
25933
43229
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040636.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;938
---

Melphalan
ALKERAN
00004715
Alkylating Agent
DNA



Y
23742
42789
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050468.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1195
---

Chorambucil
LEUKERAN
00004626
Alkylating Agent
DNA



Y
21185
43040
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052423.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;1193
---

Exemestane
AROMASIN
02242705
Aromatase Inhibitor
Aromatase



Y
36755
38307
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00044156.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;66502
---

Letrozole
FEMARA
02231384
Aromatase Inhibitor
Aromatase



Y
35660
35675
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040278.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;50695
---

Anastrazole
ARIMIDEX
02224135
Aromatase Inhibitor
Aromatase



Y
35307
37281
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062049.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;43395
---

Venetoclax
VENCLEXTA
02458039
BCL2 Inhibitor
B Cell Lymphocyte 2 (BCL2)



Y
42674
42674
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059710.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94509
---

Ponatininb
ICLUSIG
02437333
BCR-ABL Inhibitor
BCR-ABL



Y
42237
42237
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052729.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;92168
---

Bosutinib
BOSULIF
02419149
BCR-ABL Inhibitor
BCR-ABL



Y
41753
41753
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052636.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90368
---

Nilotinib
TASIGNA
02315874
BCR-ABL Inhibitor
BCR-ABL



Y
39721
39721
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058886.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;80138
---

Dasatinib
SPRYCEL
02293129
BCR-ABL Inhibitor
BCR-ABL



Y
39185
39185
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057843.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;77850
---

Imatinib
GLEEVEC
02253275
BCR-ABL Inhibitor
BCR-ABL



Y
38447
38447
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00053452.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;73824
---

Dabrafenib
TAFINLAR
02409607
BRAF Inhibitor
BRAF



Y
41514
42640
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060490.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89429
---

Vemurafenib
ZELBORAF
02380242
BRAF Inhibitor
BRAF



Y
40973
40973
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054278.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86606
---

Osimertinib
TAGRISSO
02456214
EGFR Inhibitor
Epidermal Growth Factor Receptor



Y
42570
42570
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059644.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94310
---

Afatinib
GIOTRIF
02415666
EGFR Inhibitor
Epidermal Growth Factor Receptor



Y
41656
41656
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00051644.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90026
---

Erlotinib
TARCEVA
02269007
EGFR Inhibitor
Epidermal Growth Factor Receptor



Y
39087
39087
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00047154.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;75441
---

Gefitinib
IRESSA
02248676
EGFR Inhibitor
EGFR



Y
37972
37972
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060650.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;73040
---

Abiraterone
ZYTIGA
02457113
Enzyme inhibitor
Androgen Pathway - inhibits CYP 17



Y
42635
42635
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059559.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;94420
---

Romidepsin
ISTODAX
02414295
HDAC Inhibitor
Histone Deacetylase (HDAC)



N
41675
41675
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052382.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89895
---

Apalutamide
ERLEADA
02478374
Hormonal Agent
Androgen Pathway



Y
43308
43308
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00062050.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;96913
---

Enzalutamide
XTANDI
02407329
Hormonal Agent
Androgen Pathway



Y
41432
41432
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00057056.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89203
---

Flutamide
EUFLEX
02238560
Hormonal Agent
Androgen Pathway



Y
36076
43976
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00050081.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;61987
---

Nilutamide
ANANDRON
02221861
Hormonal Agent
Androgen Pathway



Y
35662
43983
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055916.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;43312
---

Bicalutamide
CASODEX
02184478
Hormonal Agent
Androgen Receptor



Y
35430
37270
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00040132.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;19647
---

Tamoxifen
TAMOFEN
00812404
Hormonal Agent
Estrogen Receptor



Y
32873
32873
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043973.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;10664
---

Pomalidomide
POMALYST
02419580
Immunomodulator
T, NK NKT, Cytokines Misc



Y
41694
41694
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00059857.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;90423
---

Thalidomide
THALOMID
02355191
Immunomodulator
Misc



Y
40483
40483
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060578.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;84045
---

Lenalidomide
REVLIMID
02304899
Immunomodulator
T, NK NKT, Cytokines Misc



Y
39497
39497
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052749.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;79016
---

Ruxolitinib
JAKAVI
02388006
JAK1&#x2F;2 Kinase Inhibitor
Janus Kinases 1&#x2F;2



Y
41109
41109
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00061980.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;87357
---

Cobimetinib
COTELLIC
02452340
MEK1&#x2F;2 Inhibitor
MEK1&#x2F;2 Kinase



Y
42466
42466
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00043025.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;93872
---

Trametinib
MEKINIST
02409623
MEK1&#x2F;2 Inhibitor
MEK1&#x2F;2 Kinase



Y
41514
42555
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060493.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89431
---

Arsenic Trioxide
TRISENOX
02407833
Misc
Misc



N
41526
43300
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00058402.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;89255
---

Dexamethasone
DECADRON
02023865
Misc
Misc



Y
34699
34699
<a href="">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;16262
---

Prednisone

00312770
Misc
Misc



Y
30316
30316
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00030893.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;4732
---

Mitotane
LYSODREN
00463221
MIsc
Adrenocortical carcinoma



Y
29220
44230
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055613.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;3348
---

Temsirolimus
TORISEL
02304104
mTOR Inhibitor
Mammalian Target of Rapamycin



N
39458
40735
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00037735.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;78941
---

Everolimus
AFINITOR
02425645
mTOR Inhibitor
Mammalian Target of Rapamycin



Y
41971
41971
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00060902.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;91028
---

Etoposide
VEPESID
00616192
Topoisomerase II Inhibitor
DNA



Y
31047
43832
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054405.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;5963
---

Cabozantinib
CABOMETYX
02480824
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
43383
43383
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00056366.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;97148
---

Regorafenib
STIVARGA
02403390
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
41366
41366
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055344.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;88820
---

Vandetanib
CAPRELSA
02378582
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
40962
43039
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055721.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;86437
---

Pazopanib
VOTRIENT
02352303
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
40403
42620
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055255.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;83758
---

Sorafenib
NEXAVAR
02284227
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
38929
38929
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00055343.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;76977
---

Sunitinib
SUTENT
02280795
Tyrosine Kinase Inhibitor
Tyrosine Kinsase



Y
38890
38890
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00052172.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;76647
---

Axitinib
INLYTA
02389630
VEGF Inhibitor
VEGF Receptor (1,2,3)



Y
41138
41138
<a href="https:&#x2F;&#x2F;pdf.hres.ca&#x2F;dpd_pm&#x2F;00054598.PDF">HC Link</a>
https:&#x2F;&#x2F;health-products.canada.ca&#x2F;dpd-bdpp&#x2F;info.do?lang&#x3D;en&amp;code&#x3D;87513
---
